Drug intelligence / Profile preview

MVA-nef

Development stage: Phase 2
Lead developer: Bavarian Nordic
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

MVA-nef is a therapeutic HIV vaccine candidate developed by Bavarian Nordic. It utilizes the Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN) viral vector platform to deliver the HIV-1 Nef (Negative Factor) protein. The Nef protein is an early-expressed HIV protein that plays a crucial role in viral replication and immune evasion. By expressing Nef, the vaccine aims to induce a robust Nef-specific cellular immune response (T-cell response) in HIV-1 infected individuals, potentially helping to control the viral load or eliminate infected cells. It has been evaluated in Phase II clinical trials for HIV-1 infected patients with CD4 counts > 250/µl.

Other names: Modified Vaccinia Ankara-nefMVA-BN-nef

Targets

Nef (HIV-1 Nef)

Beyond the preview

Go deeper on MVA-nef.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-nef.

Explore the full profile